Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontuxizumab with Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma
NCT01574716Phase 2Completed
- Sponsor
- Morphotek
- Start
- Aug 2012
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of ontuxizumab in soft tissue sarcoma (STS), sponsored by Morphotek. Started Aug 2012; status: completed.
02
Drugs
ontuxizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01574716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01574716.